Drug Detail:Brodalumab (Brodalumab [ broe-dal-ue-mab ])
Drug Class: Interleukin inhibitors
Brodalumab Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of brodalumab during breastfeeding. Because brodalumab is a large protein molecule with a molecular weight of about 144,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, brodalumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Psoriasis) Adalimumab; Infliximab; Phototherapy
References
- 1.
-
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]
Substance Identification
Substance Name
Brodalumab
CAS Registry Number
1174395-19-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal
Dermatologic Agents
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification